Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Oct;57(10):1548-1555.
doi: 10.1038/s41409-022-01666-x. Epub 2022 Jul 13.

Impact of Anti-T-lymphocyte globulin dosing on GVHD and Immune reconstitution in matched unrelated myeloablative peripheral blood stem cell transplantation

Radwan Massoud  1 , Evgeny Klyuchnikov  1 , Nico Gagelmann  1 , Tatiana Zabelina  1 , Christine Wolschke  1 , Francis Ayuk  1 , Ulrike Fritzsche-Friedland  1 , Axel Zander  1 , Nicolaus Kröger  2
Affiliations

Impact of Anti-T-lymphocyte globulin dosing on GVHD and Immune reconstitution in matched unrelated myeloablative peripheral blood stem cell transplantation

Radwan Massoud et al. Bone Marrow Transplant. 2022 Oct.

Abstract

Data on the influence of different Anti-lymphocyte globulin (ATLG) doses on graft versus host disease (GVHD) incidence and immune reconstitution in matched unrelated (MUD) allogeneic Stem cell transplantation (allo-SCT) is limited. This retrospective study conducted at the University Medical-Center Hamburg compares GVHD and Immune reconstitution after myeloablative MUD (HLA 10/10) PBSC allogeneic stem cell transplant between 30 mg/Kg (n = 73) and 60 mg/Kg (n = 216) ATLG. Detailed phenotypes of T, B natural killer (NK), natural killer T (NKT) cells were analyzed by multicolor flow at day 30, 100, and 180 posttransplant. Neutrophil and platelet engraftments were significantly delayed in the 60 mg/kg group with a higher Cumulative incidence of Infections (67% vs 75% p = 0.049) and EBV (21% vs 41% p = 0.049) reactivation at day 100 in this group. In the 30 mg/kg group, we observed a faster reconstitution of naïve-B cells (p < 0.0001) and γδ T cells (p = 0.045) at day+30 and a faster naïve helper T-cell (p = 0.046), NK-cells (p = 0.035), and naïve B-cell reconstitution (p = 0.009) at day+180. There were no significant differences in aGVHD, cGVHD, NRM, RI, PFS, and OS between the groups. The choice of ATLG dose has significant impact on IR but not on GVHD after MUD-allo-SCT. Higher doses are associated with delayed engraftment and increased infections.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Figures

Fig. 1
Fig. 1. Comparison of two different ATLG dose for GvHD Prevention after unrelated allogeneic stem cell transplantation.
a Comparison of neutrophil engraftment between 30 mg/kg and 60 mg/kg ATLG. b Incidence of infections after 30 mg/kg and 60 mg/kg ATLG.
Fig. 2
Fig. 2. Comparison of two different ATLG dose for GvHD Prevention after unrelated allogeneic stem cell transplantation.
a comparison of overall survival (OS) between 30 mg/kg and 60mg/kg ATLG. b comparison of disese-free survival (DFS between 30 mg/kg and 60 mg/kg ATLG and c comparison of cumulative incidence of non-relapse mortality (NRM) between 30 mg/kg and 60 mg/kg ATLG.
Fig. 3
Fig. 3. Comparison of two different ATLG dose for GvHD Prevention after unrelated allogeneic stem cell transplantation.
Comparison of imnune reconstitution between 30 mg/kg and 60 mg/kg ATLG after transplantation regarding (a) gamma-delta T cells (b) naive T cells c Natural Killer (NK) cells and d naive B-cells.
Fig. 4
Fig. 4. Comparison of Immune reconstitution.
a of gamma-delta T cells post allo-SCT between 30 mg/Kg ATLG vs 60 mg/Kg ATLG. b of naïve T cells post allo-SCT between 30 mg/Kg ATLG vs 60 mg/Kg ATLG. c of NK-Cells post allo-SCT between 30 mg/Kg ATLG vs 60 mg/Kg ATLG. d of naïve B-cells post allo-SCT between 30 mg/Kg ATLG vs 60 mg/Kg ATLG.
See this image and copyright information in PMC

References

    1. Copelan EA. Hematopoietic stem-cell transplantation. N Engl J Med. 2006;354:1813–26. doi: 10.1056/NEJMra052638. - DOI - PubMed
    1. Horowitz MM, Gale RP, Sondel PM, Goldman JM, Kersey J, Kolb HJ, et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood. 1990;75:555–62. doi: 10.1182/blood.V75.3.555.555. - DOI - PubMed
    1. Glucksberg H, Storb R, Fefer A, Buckner CD, Neiman PE, Clift RA, et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation. 1974;18:295–304. doi: 10.1097/00007890-197410000-00001. - DOI - PubMed
    1. Bonifazi F, Solano C, Wolschke C, Sessa M, Patriarca F, Zallio F, et al. Acute GVHD prophylaxis plus ATLG after myeloablative allogeneic haemopoietic peripheral blood stem-cell transplantation from HLA-identical siblings in patients with acute myeloid leukaemia in remission: final results of quality of life and long-term outcome analysis of a phase 3 randomised study. Lancet Haematol. 2019;6:e89–e99. doi: 10.1016/S2352-3026(18)30214-X. - DOI - PubMed
    1. Finke J, Bethge WA, Schmoor C, Ottinger HD, Stelljes M, Zander AR, et al. Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial. Lancet Oncol. 2009;10:855–64. doi: 10.1016/S1470-2045(09)70225-6. - DOI - PubMed

Publication types

MeSH terms